{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:11:43Z","timestamp":1792807903530,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41390-025-04430-1","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:20:12Z","timestamp":1758298812000},"page":"2634-2639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Urine neutrophil gelatinase-associated lipocalin predicts kidney support therapy duration and liberation in critically ill children"],"prefix":"10.1038","volume":"99","author":[{"given":"Giovanni","family":"Ceschia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja M.","family":"Gist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen","family":"Clover-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli A.","family":"Krallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"4430_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamapediatrics.2017.4540","volume":"172","author":"R Alobaidi","year":"2018","unstructured":"Alobaidi, R. et al. Association between fluid balance and outcomes in critically ill children: a systematic review and meta-analysis. JAMA Pediatr. 172, 257\u2013268 (2018).","journal-title":"JAMA Pediatr."},{"key":"4430_CR2","doi-asserted-by":"publisher","first-page":"e2349871","DOI":"10.1001\/jamanetworkopen.2023.49871","volume":"7","author":"KM Gist","year":"2024","unstructured":"Gist, K. M. et al. Time to continuous renal replacement therapy initiation and 90-day major adverse kidney events in children and young adults. JAMA Netw. Open 7, e2349871 (2024).","journal-title":"JAMA Netw. Open"},{"key":"4430_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2751-8","volume":"24","author":"RJ Katulka","year":"2020","unstructured":"Katulka, R. J. et al. Determining the optimal time for liberation from renal replacement therapy in critically ill patients: a systematic review and meta-analysis (DOnE RRT). Crit. Care 24, 50 (2020).","journal-title":"Crit. Care"},{"key":"4430_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1159\/000532034","volume":"52","author":"T Yoshida","year":"2023","unstructured":"Yoshida, T. et al. Different roles of functional and structural renal markers measured at discontinuation of renal replacement therapy for acute kidney injury. Blood Purif. 52, 786\u2013792 (2023).","journal-title":"Blood Purif."},{"key":"4430_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01137-6","volume":"13","author":"Y Komaru","year":"2023","unstructured":"Komaru, Y. et al. Urinary neutrophil gelatinase-associated lipocalin and plasma IL-6 in discontinuation of continuous venovenous hemodiafiltration for severe acute kidney injury: a multicenter prospective observational study. Ann. Intensive Care 13, 42 (2023).","journal-title":"Ann. Intensive Care"},{"key":"4430_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04217-4","volume":"26","author":"T von Groote","year":"2022","unstructured":"von Groote, T. et al. Proenkephalin A 119\u2013159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial. Crit. Care 26, 333 (2022).","journal-title":"Crit. Care"},{"key":"4430_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04556-w","volume":"27","author":"T von Groote","year":"2023","unstructured":"von Groote, T. et al. Evaluation of Proenkephalin A 119\u2013159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury. Crit. Care 27, 276 (2023).","journal-title":"Crit. Care"},{"key":"4430_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00134-019-05919-0","volume":"46","author":"E Hoste","year":"2020","unstructured":"Hoste, E. et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med 46, 943\u2013953 (2020).","journal-title":"Intensive Care Med"},{"key":"4430_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03618-1","volume":"25","author":"SM Bagshaw","year":"2021","unstructured":"Bagshaw, S. M. et al. External validation of urinary C\u2013C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury. Crit. Care 25, 185 (2021).","journal-title":"Crit. Care"},{"key":"4430_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04610-7","volume":"27","author":"YT Chen","year":"2023","unstructured":"Chen, Y. T. et al. Performance of urinary C\u2013C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis. Crit. Care 27, 318 (2023).","journal-title":"Crit. Care"},{"key":"4430_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/CCM.0000000000005849","volume":"51","author":"M Meersch","year":"2023","unstructured":"Meersch, M. et al. Predicting the development of renal replacement therapy indications by combining the furosemide stress test and chemokine (C-C Motif) ligand 14 in a cohort of postsurgical patients. Crit. Care Med. 51, 1033\u20131042 (2023).","journal-title":"Crit. Care Med."},{"key":"4430_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00134-024-07336-4","volume":"50","author":"EK Stenson","year":"2024","unstructured":"Stenson, E. K. et al. Factors associated with successful liberation from continuous renal replacement therapy in children and young adults: analysis of the worldwide exploration of renal replacement outcomes collaborative in Kidney Disease Registry. Intensive Care Med 50, 861\u2013872 (2024).","journal-title":"Intensive Care Med"},{"key":"4430_CR13","doi-asserted-by":"publisher","first-page":"E2246901","DOI":"10.1001\/jamanetworkopen.2022.46901","volume":"5","author":"M Daverio","year":"2022","unstructured":"Daverio, M. et al. Continuous kidney replacement therapy practices in pediatric intensive care units across Europe. JAMA Netw. Open 5, E2246901 (2022).","journal-title":"JAMA Netw. Open"},{"key":"4430_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/1744-9987.13958","volume":"27","author":"T Haga","year":"2023","unstructured":"Haga, T., Ide, K. & Tani, M. Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan. Ther. Apheresis Dial. 27, 562\u2013570 (2023).","journal-title":"Ther. Apheresis Dial."},{"key":"4430_CR15","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1007\/s00467-022-05864-z","volume":"38","author":"DY Fuhrman","year":"2023","unstructured":"Fuhrman, D. Y., Gist, K. M. & Akcan-Arikan, A. Current practices in pediatric continuous kidney replacement therapy: a systematic review-guided multinational modified Delphi consensus study. Pediatr. Nephrol. 38, 2817\u20132826 (2023).","journal-title":"Pediatr. Nephrol."},{"key":"4430_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/PCC.0000000000003477","volume":"25","author":"KM Gist","year":"2024","unstructured":"Gist, K. M. et al. Continuous renal replacement therapy: current state and future directions for worldwide practice. Pediatr. Crit. Care Med. 25, 554\u2013560 (2024).","journal-title":"Pediatr. Crit. Care Med."},{"key":"4430_CR17","doi-asserted-by":"publisher","first-page":"E2229442","DOI":"10.1001\/jamanetworkopen.2022.29442","volume":"5","author":"SL Goldstein","year":"2022","unstructured":"Goldstein, S. L. et al. Consensus-based recommendations on priority activities to address acute kidney injury in children: a modified Delphi Consensus statement. JAMA Netw. Open 5, E2229442 (2022).","journal-title":"JAMA Netw. Open"},{"key":"4430_CR18","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.ekir.2023.09.019","volume":"8","author":"SL Goldstein","year":"2023","unstructured":"Goldstein, S. L. et al. Real-time acute kidney injury risk stratification\u2013biomarker directed fluid management improves outcomes in critically ill children and young adults. Kidney Int. Rep. 8, 2690\u20132700 (2023).","journal-title":"Kidney Int. Rep."},{"key":"4430_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 61, 344\u2013349 (2008).","journal-title":"J. Clin. Epidemiol."},{"key":"4430_CR20","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/00003246-200208000-00016","volume":"30","author":"DA Schoenfeld","year":"2002","unstructured":"Schoenfeld, D. A. & Bernard, G. R. ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit. Care Med. 30, 1772\u20131777 (2002).","journal-title":"Crit. Care Med."},{"key":"4430_CR21","doi-asserted-by":"publisher","unstructured":"Billings Iv F. T. & Shaw A. D. Clinical trial endpoints in acute kidney injury. in Nephron - Clinical Practice. Vol 127 (S. Karger AG, 2014) 89\u201393. https:\/\/doi.org\/10.1159\/000363725","DOI":"10.1159\/000363725"},{"key":"4430_CR22","first-page":"1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum, J. A. et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2, 1\u2013138 (2012).","journal-title":"Kidney Int. Suppl."},{"key":"4430_CR23","doi-asserted-by":"publisher","first-page":"E240243","DOI":"10.1001\/jamanetworkopen.2024.0243","volume":"7","author":"DY Fuhrman","year":"2024","unstructured":"Fuhrman, D. Y. et al. Major adverse kidney events in pediatric continuous kidney replacement therapy. JAMA Netw. Open 7, E240243 (2024).","journal-title":"JAMA Netw. Open"},{"key":"4430_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.ajkd.2023.12.017","volume":"84","author":"MC Starr","year":"2024","unstructured":"Starr, M. C. et al. Continuous kidney replacement therapy and survival in children and young adults: findings from the multinational WE-ROCK collaborative. Am. J. Kidney Dis. 84, 406\u2013415.e1 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"4430_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nm.2290","volume":"17","author":"N Paragas","year":"2011","unstructured":"Paragas, N. et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat. Med. 17, 216\u2013222 (2011).","journal-title":"Nat. Med."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04430-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04430-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04430-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:01:00Z","timestamp":1787047260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04430-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4430"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04430-1","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SLG reports receiving personal fees from Baxter Healthcare, BioPorto Diagnostics, Calcimedica, Fresenius, Novartis, Nuwellis, MediBeacon, Medtronic, Otsuka and SeaStar Medical. KMG reports receiving funding from the Gerber Foundation for the MINI-ROCKET study and is a consultant for Bioporto Diagnostics. She is a member of the Medical Advisory Board for SeaStar Medical and received speaker honoraria from Fresenius. None of these entities had any input into the study or manuscript, and these relationships are not relevant to the manuscript. No other disclosures were reported.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}